iApotheca Healthcare Inc. Announces Closing of $470K Angel Funding Round

iApotheca Healthcare, the developers of a leading Canadian pharmacy software operations platform, has announced the closing of a $470k angel funding round. iApotheca will use the funds to accelerate their EconoRoute™ Prescription Delivery System through the addition of key team members, ongoing platform development and the expansion of the EconoRoute™ network.

“Prescription delivery is revolutionizing the way people interact with their chosen pharmacy,” said Spencer Turbitt, co-founder and CEO of iApotheca. “We would like to thank Leva Capital, York Angels, and Valhalla Angels for their investment in our company. Their investment and advice are allowing us to accelerate our plans to achieve our vision for the pharmacy delivery space.”

iApotheca specializes in streamlining pharmacy operations, particularly in prescription delivery service, to help pharmacies grow their revenue. In recent years, the demand for prescription delivery has seen a sharp rise. iApotheca’s EconoRoute™ prescription delivery software supports the demand with an easy-to-use, low-cost, one-stop solution for pharmacies of all sizes.

“Leva Capital is thrilled to announce the addition of iApotheca into our investment portfolio,” said Eddie Gobran, Managing Partner. “Their strategy aligns with our vision of investing in health technology that will improve the healthcare experience for Canadians. We are confident in iApotheca’s team to execute their strategy and deliver a great experience to pharmacies across Canada.”

EconoRoute™ includes features that make it an ideal delivery solution for any business. Its unique physics-based instant routing and real-time driver tracking are high-performance tools. Built-in pay-at-the-door functionality also makes it easy for businesses to track accounting.

iApotheca’s years of expertise in supporting pharmacies in doing business more efficiently make EconoRoute™ more than just another prescription delivery service.  The software has the added benefit of built-in compliance tools, cold-chain prioritization, and inherent patient privacy measures, all crucial for compliance. Taken together, these tools make EconoRoute™ a must-have for prescription delivery.

“Willowgrove Pharmacy has been using EconoRoute™ since its inception. After spending much time researching delivery platforms, EconoRoute™ came out the clear winner,” said Devon Elias, owner of Willowgrove Pharmacy in Manitoba. “The application does everything we need it to do. Optimization of routes, easy set up of regular repeat deliveries, tracking and signature requirements are all in one application, allowing for a single program to be our delivery central. Willowgrove Pharmacy employs three full-time positions for delivery of product and services and EconoRoute™ easily organizes it all.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”